MX392515B - Compuestos inhibidores de beta-lactamasa - Google Patents
Compuestos inhibidores de beta-lactamasaInfo
- Publication number
- MX392515B MX392515B MX2021010077A MX2021010077A MX392515B MX 392515 B MX392515 B MX 392515B MX 2021010077 A MX2021010077 A MX 2021010077A MX 2021010077 A MX2021010077 A MX 2021010077A MX 392515 B MX392515 B MX 392515B
- Authority
- MX
- Mexico
- Prior art keywords
- sup
- beta
- inhibiting compounds
- compounds
- pharmaceutically acceptable
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
- A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B43/00—Formation or introduction of functional groups containing nitrogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D211/78—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/0834—Compounds having one or more O-Si linkage
- C07F7/0892—Compounds with a Si-O-N linkage
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662395464P | 2016-09-16 | 2016-09-16 | |
| US201762456423P | 2017-02-08 | 2017-02-08 | |
| PCT/US2017/051692 WO2018053215A1 (en) | 2016-09-16 | 2017-09-15 | Beta-lactamase inhibitor compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2021010077A MX2021010077A (es) | 2022-05-23 |
| MX392515B true MX392515B (es) | 2025-03-24 |
Family
ID=60083416
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021010077A MX392515B (es) | 2016-09-16 | 2017-09-15 | Compuestos inhibidores de beta-lactamasa |
| MX2019003060A MX385507B (es) | 2016-09-16 | 2017-09-15 | Compuestos inhibidores de beta-lactamasa |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019003060A MX385507B (es) | 2016-09-16 | 2017-09-15 | Compuestos inhibidores de beta-lactamasa |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US10800778B2 (https=) |
| EP (1) | EP3512851B1 (https=) |
| JP (2) | JP6997178B2 (https=) |
| KR (2) | KR102537340B1 (https=) |
| CN (2) | CN109715630B (https=) |
| AU (1) | AU2017325863B2 (https=) |
| CA (1) | CA3036557A1 (https=) |
| CY (1) | CY1125826T1 (https=) |
| DK (1) | DK3512851T3 (https=) |
| ES (1) | ES2927986T3 (https=) |
| HR (1) | HRP20221217T1 (https=) |
| HU (1) | HUE060282T2 (https=) |
| IL (2) | IL289686B2 (https=) |
| LT (1) | LT3512851T (https=) |
| MA (1) | MA46242A (https=) |
| MX (2) | MX392515B (https=) |
| PH (1) | PH12019500558B1 (https=) |
| PL (1) | PL3512851T3 (https=) |
| PT (1) | PT3512851T (https=) |
| SG (1) | SG11201901658PA (https=) |
| SI (1) | SI3512851T1 (https=) |
| SM (1) | SMT202200397T1 (https=) |
| TW (1) | TWI773687B (https=) |
| WO (1) | WO2018053215A1 (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX389349B (es) | 2016-06-30 | 2025-03-20 | Qpex Biopharma Inc | Derivados de ácido borónico y usos terapéuticos de los mismos. |
| DK3512851T3 (en) * | 2016-09-16 | 2022-10-17 | Entasis Therapeutics Ltd | Beta-lactamase inhibitor compounds |
| WO2018208769A1 (en) | 2017-05-08 | 2018-11-15 | Entasis Therapeutics, Inc. | Compounds and methods for treating bacterial infections |
| EP3781576B1 (en) | 2018-04-20 | 2024-06-12 | Qpex Biopharma, Inc. | Boronic acid derivatives and therapeutic uses thereof |
| EP3833665B1 (en) | 2018-08-09 | 2023-07-19 | Antabio SAS | Diazabicyclooctanones as inhibitors of serine beta-lactamases |
| US11905286B2 (en) | 2018-08-09 | 2024-02-20 | Antabio Sas | Diazabicyclooctanones as inhibitors of serine beta-lactamases |
| CN112209928B (zh) * | 2019-07-10 | 2023-02-17 | 华东理工大学 | 共价键标记丝氨酸类beta-内酰胺酶的试剂及制备和应用 |
| CN110898999A (zh) * | 2019-11-26 | 2020-03-24 | 中国矿业大学 | 一种煤焦油基煤泥浮选药剂及其制备方法 |
| AU2021266715A1 (en) | 2020-05-05 | 2022-11-17 | Qpex Biopharma, Inc. | Boronic acid derivatives and synthesis, polymorphic forms, and therapeutic uses thereof |
| CN111790439B (zh) * | 2020-07-29 | 2022-12-27 | 成都能特科技发展有限公司 | 一种手性二级胺二苯基膦芳甲酰胺双功能催化剂及其制备方法与应用 |
| CN115151544B (zh) | 2020-09-01 | 2024-08-16 | 宁夏农林科学院 | β-内酰胺酶抑制剂及其制备 |
| JP2024512793A (ja) * | 2021-04-05 | 2024-03-19 | キューペックス バイオファーマ， インコーポレイテッド | セフチブテン投与レジメン |
| CN115605480B (zh) | 2021-05-07 | 2024-04-05 | 宁夏农林科学院 | 磺酰脒取代的化合物及其作为β-内酰胺酶抑制剂的用途 |
| US11814385B2 (en) | 2021-06-25 | 2023-11-14 | University Of South Florida | Small molecule inhibitors targeting Clostridioides difficile sporulation |
| WO2023206580A1 (en) | 2022-04-29 | 2023-11-02 | Entasis Therapeutics Limited | Durlobactam crystalline forms |
| US20230398101A1 (en) * | 2022-06-09 | 2023-12-14 | Fleurir Abx Llc | Co-agents as Therapy Against Anaerobic Pathogens |
| CN118271319B (zh) * | 2022-12-30 | 2025-02-28 | 成都四面体药物研究有限公司 | 一种β-内酰胺酶抑制剂含脲双环化合物、其制备方法及其用途 |
| CN118772145B (zh) * | 2023-04-04 | 2025-10-10 | 上海医药工业研究院有限公司 | 一种二氮杂双环辛烯化合物的制备方法 |
| CN116693531A (zh) * | 2023-06-09 | 2023-09-05 | 河南师范大学 | 一种桥联多环内酰胺类化合物的合成方法 |
| WO2025106662A1 (en) * | 2023-11-15 | 2025-05-22 | Entasis Therapeutics, Inc. | Preparation of boronic acid intermediates useful for the preparation of compounds for treating bacterial infections |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4607041A (en) * | 1983-04-27 | 1986-08-19 | Fisons Plc | Antihypertensive 2-phenyl Hantzsch dihydropyridines |
| CZ282567B6 (cs) | 1993-12-29 | 1997-08-13 | Pfizer Inc. | Diazabicyklické sloučeniny a farmaceutické prostředky na jejich bázi |
| FR2812635B1 (fr) | 2000-08-01 | 2002-10-11 | Aventis Pharma Sa | Nouveaux composes heterocycliques, preparation et utilisation comme medicaments notamment comme anti- bacteriens |
| FR2825705B1 (fr) * | 2001-06-08 | 2005-05-20 | Aventis Pharma Sa | Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens |
| FR2835186B1 (fr) | 2002-01-28 | 2006-10-20 | Aventis Pharma Sa | Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases |
| FR2848210B1 (fr) | 2002-12-06 | 2007-10-19 | Aventis Pharma Sa | Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens et inhibiteurs de beta-lactamases |
| US7439253B2 (en) | 2002-12-06 | 2008-10-21 | Novexel | Heterocyclic compounds, their preparation and their use as medicaments, in particular as antibacterials and beta-lactamase inhibitors |
| FR2914923B1 (fr) | 2007-04-12 | 2013-06-14 | Novexel | Nouveaux composes heterocycliques azotes,leur preparation et leur utilisation comme medicaments antibacteriens. |
| WO2009091856A2 (en) * | 2008-01-18 | 2009-07-23 | Merck & Co., Inc. | Beta-lactamase inhibitors |
| FR2930553B1 (fr) | 2008-04-29 | 2010-05-21 | Novexel | Composes azabicycliques, leur preparation et leur utilisation comme medicaments, notamment inhibiteurs de beta-lactamases |
| EP2921559A1 (en) | 2008-06-19 | 2015-09-23 | Astra Zeneca Holding France | Use of (1r,2s,5r) 1,6-diazabicyclo [3.2.1]octane-2-carboxamide, 7-oxo-6-(sulfooxy)-, monosodium salt as a diagnostic reagent for detecting serine beta-lactamases |
| FR2936798B1 (fr) | 2008-10-03 | 2012-09-28 | Novexel | Nouveaux composes heterocycliques azotes, leur preparation et leur utilisation comme medicaments antibacteriens. |
| FR2937034B1 (fr) | 2008-10-10 | 2012-11-23 | Novexel | Nouveaux composes heterocycliques azotes, leur preparation et leur utilisation comme medicaments antibacteriens |
| FR2936951B1 (fr) | 2008-10-10 | 2010-12-03 | Novexel | Nouvelles combinaisons de composes heterocycliques azotes antibacteriens avec d'autres composes antibacteriens et leur utilisation comme medicaments |
| FR2951171A1 (fr) | 2009-10-09 | 2011-04-15 | Novexel | Nouveau sel de sodium d'un compose azabicyclique sous forme enantiomere cristallisee et nouvelles formes polymorphes et pseudopolymorphes ainsi que leur preparation |
| CA2796750C (en) * | 2010-04-20 | 2017-09-19 | Taisho Pharmaceutical Co., Ltd. | Novel hydroxamic acid derivative |
| WO2013014497A1 (en) | 2011-07-26 | 2013-01-31 | Wockhardt Limited | Pharmaceutical compositions comprising beta-lactam antibiotic, sulbactam and beta-lactamase inhibitor |
| NZ616806A (en) | 2011-07-26 | 2015-03-27 | Wockhardt Ltd | Pharmaceutical compositions comprising sulbactam and beta-lactamase inhibitor |
| MX348974B (es) * | 2011-08-27 | 2017-07-04 | Wockhardt Ltd | Derivados 1,6 - diazabiciclo [3,2,1] octan-7-ona y su uso en el tratamiento de infecciones bacterianas. |
| CA2845108C (en) | 2011-08-30 | 2015-06-16 | Wockhardt Limited | 1,6-diazabicyclo[3,2,1]octan-7-one derivatives and their use in the treatment of bacterial infections |
| CA2846107C (en) | 2011-09-13 | 2016-06-21 | Wockhardt Limited | Nitrogen containing compounds and their use |
| US8796257B2 (en) | 2011-12-02 | 2014-08-05 | Naeja Pharmaceutical Inc. | Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors |
| EP2814483A2 (en) | 2012-02-15 | 2014-12-24 | Rempex Pharmaceuticals, Inc. | Methods of treating bacterial infections |
| WO2013149136A1 (en) | 2012-03-30 | 2013-10-03 | Cubist Pharmaceuticals, Inc. | ISOXAZOLE β-LACTAMASE INHIBITORS |
| US8940897B2 (en) | 2012-03-30 | 2015-01-27 | Cubist Pharmaceuticals, Inc. | 1,3,4-oxadiazole and 1,3,4-thiadiazole β-lactamase inhibitors |
| US8969570B2 (en) | 2012-03-30 | 2015-03-03 | Cubist Pharmaceuticals, Inc. | Beta-lactamase inhibitors |
| US8916709B2 (en) | 2012-03-30 | 2014-12-23 | Cubist Pharmaceuticals, Inc. | 1,2,4-oxadiazole and 1,2,4-thiadiazole β-lactamase inhibitors |
| AR090539A1 (es) * | 2012-04-02 | 2014-11-19 | Astrazeneca Ab | COMPUESTOS INHIBIDORES DE b LACTAMASA |
| HUE046893T2 (hu) | 2012-05-30 | 2020-04-28 | Meiji Seika Pharma Co Ltd | Új ß-laktamáz inhibitor és eljárás elõállítására |
| RU2614418C2 (ru) | 2012-08-25 | 2017-03-28 | Вокхардт Лимитед | Производные 1,6-диазабицикло[3.2.1]октан-7-она и их применение для лечения бактериальных инфекций |
| US20150258072A1 (en) | 2012-09-03 | 2015-09-17 | Wockhardt Limited | Antibacterial compositions |
| EP2953626A1 (en) | 2013-02-06 | 2015-12-16 | Astrazeneca AB | Combination therapy for the treatment of nosocomial pneumonia |
| WO2014141132A1 (en) | 2013-03-14 | 2014-09-18 | Naeja Pharmaceutical Inc. | NEW HETEROCYCLIC COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS AND β-LACTAMASE INHIBITORS |
| JP6764862B2 (ja) | 2014-11-17 | 2020-10-07 | エンタシス・セラピューティックス・リミテッド | 耐性細菌感染症の治療のための併用療法 |
| US10072006B2 (en) * | 2015-03-31 | 2018-09-11 | Mutabilis | Heterocyclic compounds and their use in preventing or treating bacterial infections |
| DK3512851T3 (en) * | 2016-09-16 | 2022-10-17 | Entasis Therapeutics Ltd | Beta-lactamase inhibitor compounds |
| KR20230007830A (ko) * | 2021-07-06 | 2023-01-13 | 현대자동차주식회사 | 고강성 저선팽창 열가소성 수지 조성물 및 이를 포함하는 성형체 |
-
2017
- 2017-09-15 DK DK17784063.4T patent/DK3512851T3/da active
- 2017-09-15 TW TW106131860A patent/TWI773687B/zh active
- 2017-09-15 CA CA3036557A patent/CA3036557A1/en active Pending
- 2017-09-15 PL PL17784063.4T patent/PL3512851T3/pl unknown
- 2017-09-15 KR KR1020197010376A patent/KR102537340B1/ko active Active
- 2017-09-15 CN CN201780057302.4A patent/CN109715630B/zh active Active
- 2017-09-15 SM SM20220397T patent/SMT202200397T1/it unknown
- 2017-09-15 MX MX2021010077A patent/MX392515B/es unknown
- 2017-09-15 LT LTEPPCT/US2017/051692T patent/LT3512851T/lt unknown
- 2017-09-15 CN CN202210161577.5A patent/CN114591223B/zh active Active
- 2017-09-15 US US16/333,900 patent/US10800778B2/en active Active
- 2017-09-15 PT PT177840634T patent/PT3512851T/pt unknown
- 2017-09-15 WO PCT/US2017/051692 patent/WO2018053215A1/en not_active Ceased
- 2017-09-15 JP JP2019515241A patent/JP6997178B2/ja active Active
- 2017-09-15 MX MX2019003060A patent/MX385507B/es unknown
- 2017-09-15 MA MA046242A patent/MA46242A/fr unknown
- 2017-09-15 AU AU2017325863A patent/AU2017325863B2/en active Active
- 2017-09-15 IL IL289686A patent/IL289686B2/en unknown
- 2017-09-15 KR KR1020237017457A patent/KR102667828B1/ko active Active
- 2017-09-15 HR HRP20221217TT patent/HRP20221217T1/hr unknown
- 2017-09-15 HU HUE17784063A patent/HUE060282T2/hu unknown
- 2017-09-15 SI SI201731232T patent/SI3512851T1/sl unknown
- 2017-09-15 EP EP17784063.4A patent/EP3512851B1/en active Active
- 2017-09-15 PH PH1/2019/500558A patent/PH12019500558B1/en unknown
- 2017-09-15 ES ES17784063T patent/ES2927986T3/es active Active
- 2017-09-15 SG SG11201901658PA patent/SG11201901658PA/en unknown
-
2019
- 2019-03-11 IL IL265276A patent/IL265276B/en unknown
-
2021
- 2021-12-16 JP JP2021203942A patent/JP7281527B2/ja active Active
-
2022
- 2022-10-05 CY CY20221100661T patent/CY1125826T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX392515B (es) | Compuestos inhibidores de beta-lactamasa | |
| TN2014000417A1 (en) | Heterobicyclic compounds as beta-lactamase inhibitors | |
| CY1124086T1 (el) | Παραγωγα 3-τετραζολυλ-βενζεν-1,2-δισουλφοναμιδιου ως αναστολεις μεταλλο-βητα-λακταμασης | |
| MX385731B (es) | Compuestos de biaril-monobactam y métodos de uso de los mismos para el tratamiento de infecciones bacterianas. | |
| CR20200148A (es) | Compuestos monobactámicos cromados para el tratamiento de infecciones bacterianas | |
| EA201991523A1 (ru) | Комбинированная терапия амидин-замещенными бета-лактамными соединениями и ингибиторами бета-лактамазы при инфекциях, вызванных бактериальными штаммами, резистентными к антибиотикам | |
| MX2018010878A (es) | Compuestos de aril-monobactam biciclicos y metodos de uso de los mismos para el tratamiento de infecciones bacterianas. | |
| BR112017010132A2 (pt) | terapia combinada para tratamento de infecções bacterianas resistentes | |
| MX2021001564A (es) | Diazabiciclooctanonas como inhibidores de serina beta-lactamasas. | |
| EA201992370A1 (ru) | Соединения и способы для лечения бактериальных инфекций | |
| EA201890412A1 (ru) | АНТИБАКТЕРИАЛЬНЫЕ АГЕНТЫ, СОДЕРЖАЩИЕ ПИРАЗИНО[2,3-b][1,4]ОКСАЗИН-3-ОН ИЛИ РОДСТВЕННУЮ КОЛЬЦЕВУЮ СИСТЕМУ | |
| PH12019500331A1 (en) | Beta-lactamase inhibitors | |
| MX2021003485A (es) | Derivados de indano para uso en el tratamiento de infeccion bacteriana. | |
| MX373098B (es) | Derivados de manosa para tratar infecciones bacterianas. | |
| EA201990738A1 (ru) | Соединения-ингибиторы бета-лактамаз | |
| EA202190444A1 (ru) | Диазабициклооктаноны в качестве ингибиторов сериновых бета-лактамаз | |
| EA202190585A1 (ru) | Производные индана для применения при лечении бактериальной инфекции | |
| EA202090357A1 (ru) | Химические соединения | |
| TH1701007800A (th) | ตัวยับยั้งเมทัลโล-บีตา-แลคทาเมส |